Table 6.

Clinical Studies of Glutathione Levels in Lung Cancer

Study	Ptsa	Typeb	Tumor Glutathione Levelsc	γGTd	Controle	Ratiof
(Blair et al. 1997)	20	AC, SQ, Other	20.8 ± 9.4 nmol/mg-protein	Y	P	1.8*
(Bluhm & Greschuchna 1989)	190		3.1 ± 0.3f Stage I μg/ml	Y
			3.9 ± 0.4 Stage II
			2.3 ± 0.4 Stage III
(Duarte et al. 2010)	24	AC, other		N	P	>1*
(Ferruzzi, 2003)	29	AC, SQ, Other	24.1 ± 12.0 nmol/mg-protein	Y	P	1.8*
(Ilonen et al. 2009)	22	AC	20.8 nmol/mg-protein	?	P	1.8*
		SQ	6.90			1.4
(Korotkina et al. 2002)	72	AC	5.166 ± 0.630 nmol/mg-protein	Y	H	2.9*
		SQ	4.650 ± 0.323			2.6*
		other	2.836 ± 0.521			1.6*
		benign	2.75			1.5*
(Krepela et al. 1997)	21	SQ	63.2 ± 7.0 nmol/mg-protein	Y	P	2.5*
			1.80 ± 0.23 μmol/g-tissue			2.3*
(Oberli-Schrammli et al. 1994)	55	AC	27.1 nmol/mg-protein	Y	P	3.5*
		SQ	47.2			3.9*
		LCC	57.5			4.3
		SCC	41.4			4.6*
(O’Dwyer, 1996)	4		1.91 – 33.0 nmol/mg-protein
(Rowell et al. 1989)	7	AC	1.79 mM	Y	P	2.1
		SQ	3.54			3.3
		Other	4.31			4.7
		SCC	0.84			0.59
(Saydam et al. 1997)	38	AC, SQ	3.10 ± 0.45 μmol/g-tissue	Y	P	0.86
(Toussaint et al. 1993)	12	AC, SQ, LCC	10 ± 8 nmol/mg-protein	Y	P	1.0

^aNumber of patients in the study.

^bTumor type AC, adenocarcinoma; CONT, control, cancer-free patients; SCC, small cell carcinoma; SQ, squamous cell carcinoma; LCC, large cell carcinoma.

^cConcentration of glutathione or thiols in tissue. Numbers in italics indicates reports of non-protein sulfhydryls rather than glutathione.

^dDenotes whether degradation by γ-glutamyltranspeptidase was prevented (Y) or not (N) by sample processing methods.

^eDisease free tissue from healthy controls (H); peritumoral tissue (P).

^fRatio of tumor glutathione to control tissue levels. Gray shading indicates statistically significant T/C<1

^*Asterisk indicates statistically significant difference in levels of glutathione between tumor and nontumor tissue.